CR9596A - Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion - Google Patents

Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion

Info

Publication number
CR9596A
CR9596A CR9596A CR9596A CR9596A CR 9596 A CR9596 A CR 9596A CR 9596 A CR9596 A CR 9596A CR 9596 A CR9596 A CR 9596A CR 9596 A CR9596 A CR 9596A
Authority
CR
Costa Rica
Prior art keywords
piperazinyl
amino
methyl
chinolinocarbonitrile
metoxifenil
Prior art date
Application number
CR9596A
Other languages
English (en)
Inventor
Marc Sadler Tesconi
Gregg Feigelson
Henry Strong
Hong Wen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9596(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9596A publication Critical patent/CR9596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invencion se dirige a un monohidrato cristalino de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo que tiene un patron de difraccion de rayos X en donde los angulos 20 (°) de picos significativos estan en aproximadamente: 9.19, 11.48, 14.32, 19.16, 19.45, 20,46, 21.29, 22.23, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61 y 29.51, y una temperatura de transicion de aproximadamente 109° C a aproximadamente 115° C.
CR9596A 2005-07-01 2007-12-17 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion CR9596A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
CR9596A true CR9596A (es) 2008-03-06

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9596A CR9596A (es) 2005-07-01 2007-12-17 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion

Country Status (24)

Country Link
US (2) US7767678B2 (es)
EP (1) EP1902029B2 (es)
JP (1) JP2009500332A (es)
KR (1) KR20080028386A (es)
CN (1) CN101248047A (es)
AR (1) AR054505A1 (es)
AU (1) AU2006266045A1 (es)
BR (1) BRPI0613574A2 (es)
CA (1) CA2613053C (es)
CR (1) CR9596A (es)
DK (1) DK1902029T4 (es)
EC (1) ECSP078063A (es)
ES (1) ES2449197T5 (es)
GT (1) GT200600282A (es)
IL (1) IL188483A0 (es)
MX (1) MX2008000384A (es)
NO (1) NO20080051L (es)
PA (1) PA8685101A1 (es)
PE (1) PE20070190A1 (es)
PL (1) PL1902029T5 (es)
PT (1) PT1902029E (es)
RU (1) RU2007148072A (es)
TW (1) TW200740797A (es)
WO (1) WO2007005462A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011152105A (ru) * 2009-07-02 2013-08-10 УАЙТ ЭлЭлСи Составы таблеток 3-цианохинолина и их применение
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
CA2535385A1 (en) * 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005047259A1 (en) * 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
WO2007001839A2 (en) 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
DK1902029T4 (da) 2022-02-28
AU2006266045A1 (en) 2007-01-11
AR054505A1 (es) 2007-06-27
US7767678B2 (en) 2010-08-03
CA2613053A1 (en) 2007-01-11
MX2008000384A (es) 2008-03-07
EP1902029B1 (en) 2014-01-08
ES2449197T3 (es) 2014-03-18
US20100324066A1 (en) 2010-12-23
WO2007005462A1 (en) 2007-01-11
EP1902029A1 (en) 2008-03-26
ECSP078063A (es) 2008-01-23
PA8685101A1 (es) 2007-01-17
NO20080051L (no) 2008-01-29
CN101248047A (zh) 2008-08-20
RU2007148072A (ru) 2009-08-10
PT1902029E (pt) 2014-03-05
IL188483A0 (en) 2008-04-13
KR20080028386A (ko) 2008-03-31
BRPI0613574A2 (pt) 2016-11-16
US20070015767A1 (en) 2007-01-18
ES2449197T5 (es) 2022-04-28
HK1114614A1 (en) 2008-11-07
TW200740797A (en) 2007-11-01
US8445496B2 (en) 2013-05-21
EP1902029B2 (en) 2022-02-16
GT200600282A (es) 2007-02-14
PE20070190A1 (es) 2007-03-20
PL1902029T5 (pl) 2022-08-29
JP2009500332A (ja) 2009-01-08
DK1902029T3 (en) 2014-02-17
CA2613053C (en) 2015-11-24
PL1902029T3 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
ECSP078063A (es) Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y métodos para su preparación
DK1496912T3 (da) Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse
IS7818A (is) Tafin losun á amfetamínsöltum
DK1854454T3 (da) Fremgangsmåde til fremstilling af amorf telmisartan
DK1877379T3 (da) Hydroxybenzamidderivater og anvendelse heraf som inhibitorer af hsp90
DK1940786T3 (da) Biphenylderivater og deres anvendelse ved behandling af hepatitis C
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
EP1773846A4 (en) INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX
DE60324488D1 (de) Gekühlte Gasturbinenschaufel
ID30465A (id) Mekanisme pengarah petransmisi daya selubung
CR9208A (es) Procesos para la preparacion de alcoholes de aminoetoxibencilo
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1420028T3 (da) Fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
DK1503747T3 (da) Diclofenacbaseret sammensætning til topisk behandling af sygdomme
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer
NO20054111D0 (no) Fremgangsmate for fremtilling av tibolon
EA200600454A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1753720T3 (da) Fremgangsmåde til fremstilling af perindopril og salte deraf
DE602006000468D1 (de) Gekühltes Hochleistungslaserlinsenarray

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)